Smithkline Beecham Corporation

Lilly Icos LLC

Michael Lawrence Sierra

Millard Hurst Lambert, Iii

Paul John Beswick

Vipulkumar Kantibhai Patel

Rodolfo Cadilla

Timothy Mark Willson

Marcos Sznaidman

Romain Luc Marie Gosmini

Curt Dale Haffner

Patrick Reed Maloney

Huaqiang Eric Xu

Nerina Dodic

Daniel David Sternbach

Esther Yu-Hsuan Chao

Jason Scott Sawyer

Mark W Orme

Francoise Jeanne Gellibert

Romain Luc Gosmini

Agnes Bombrun

Christopher Charles Hamlett

Nigel Grahame Ramsden

Anne Bouillot

Bernard André Dumaître

The present invention provides combinations of compounds of formula (I) and other therapeutic agents for the treatment of PPAR related diseases. 

Thiazole derivatives for treating PPAR related disorders

A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein: 

Phenyloxyalkanonic acid derivatives as hPPAR activators

A compound of formula (I) or pharmaceutically acceptable salts and solvates thereof. Rand Rare independently H or Calkyl, m is 0&#x2013;3; Xis NH, NCH, O, S; R, Rand Rare independently H, CH, CF, OCH, allyl or halogen; Xis (CRR)n wherein n is 1 or 2; Rand Rindependently represent H, fluorine or Calkyl; Rand Rare independently H, Calkyl or Rand Rtogether with the carbon atom to which they are bonded form a 3&#x2013;5 membered cycloalklyl ring. Rand Rindependently represent H, fluorine or Calkyl; Ris Calkyl or CF; One of Y and Z is N, the other is S or O; Each Rindependently represents CF, OCH, CHor halogen; y is O, 1, 2, 3, 4, 5. Use of a compound of formula (I) for the manufacture of a medicament for the prevention or treatment of a hPPAR mediated disease or condition, such as dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, type II diabetes mellitus, type 1 diabetes, insulin resistance hyperlipidemia, obesity, anorexia bulimia, inflammation and anorexia nervosa 

Thia-and oxazoles and their use as ppars activators

The present invention provides compounds of formula (I). These compounds are used for the treatment of PPAR related diseases

A compound of formula (I) or pharmaceutically acceptable salts and solvates thereof, for the treatment of a hPPAR mediated disease or condition 

Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors

Compounds of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof wherein X is O or S X1 is O or S; X is S or O; R1 and R2 are independently H, methyl, or halogen; R4 and R5 are independently H or C1-3 alkyl or R4 and R5 may, together with the carbon atom to which they are bonded, form a 3&#x2013;5 membered cycloalkyl ring; R6 and R7 are independently H, C1-3 alkyl, or allyl; each R3 is independently halogen, C1-6 straight or branched alkyl, or CF3; and y is 0, 1, 2, 3, 4 or 5 act as hPPAR alpha agonists.

Substituted oxazoles and thiazoles as hPPAR alpha agonists

Compounds of the general structural formulaand use of the compounds and salts and solvates thereof, as therapeutic agents.

Carboline derivatives

Activator of PPAR delta

Compounds of Formula (1) are disclosed. These compounds include selective activators of human PPAR delta.

Activators of PPAR delta

Growing community of inventors

Les Ulis, France

Michael Lawrence Sierra